Challenges to delivering quality care in a prevention of mother-to-child transmission of HIV programme in Soweto.
Healthcare system and patient factors are important in the scale-up and success of HIV programmes (including PMTCT) [4-7] and the availability of interventions alone is not sufficient to guarantee appropriate implementation and uptake. [4-5,8-9] Healthcare facilities need to be well-resourced with competent and motivated staff to provide the services, and there needs to be service uptake and treatment adherence by patients. [4-7] The providers' and patients' knowledge and attitudes are also important. [7,8] There is evidence to suggest that the patient-provider relationship may have an effect on decision-making during the antenatal period, and on the uptake of PMTCT interventions.  Yet, quality of care has not been a focus in most PMTCT services in SA; most are focused on increasing coverage in the PMTCT cascade. Several reviews have found poor performance and coverage in PMTCT programmes, despite the simplicity of some interventions; hence, the focus has been on increasing coverage. [5,11,12]
We conducted a cross-sectional survey to investigate key aspects of the quality of care in PMTCT services in antenatal clinics in Soweto, SA, focusing on the PMTCT programme knowledge and experiences of (i) healthcare workers and (ii) HIV-infected pregnant women accessing the services. This was performed against the backdrop of recently updated PMTCT guidelines in 2008, when zidovudine (AZT) monotherapy became available for prophylaxis. 
The study was approved by the Human Research Ethics Committee of the University of the Witwatersrand. All participants signed written informed consent to participate.
Until March 2008, all antenatal clinics in Soweto had only intrapartum single-dose nevirapine (NVP) for PMTCT for pregnant women who were not eligible for life-long ART. AZT was rolled out in phases across the antenatal clinics in March-October 2008. Prior to implementation of the guidelines, staff at the antenatal clinics, including lay counsellors, were trained on the new guidelines. The PMTCT service at each clinic was staffed by a professional nurse--a 'PMTCT co-ordinator' in charge of PMTCT services, including supervision of lay counsellors.
The study was conducted in November December 2009; all facilities had at least 12 months of routine services under the 2008 PMTCT guidelines. Participating clinics were a mixture of low--and high-volume clinics, with 50-300 pregnant women presenting to each clinic per month. The HIV prevalence was 29% in 2009, and 15-20% of pregnant women were eligible for ART under the guidelines in place at the time (criterion: [CD4.sup.+] count [less than or equal to] 200 cells/[micro]l).
HIV-infected pregnant women
Using consecutive sampling, ART-eligible and -ineligible HIV-infected pregnant women presenting to the selected antenatal clinics for repeat visits were interviewed using a structured questionnaire. Their experiences of being HIV-infected and their knowledge of available PMTCT interventions were determined. Eight key-knowledge questions were selected; each was assigned a score of 1 for a correct answer and 0 for an incorrect answer (maximum score of 8).
Healthcare workers from the same clinics were interviewed using a different questionnaire assessing their opinions and experiences of working in a PMTCT programme and their knowledge of the PMTCT guidelines. Consecutive sampling was used to select participants. Similar to the knowledge score devised for patients, a scoring system based on eight key questions was formulated. All interviewers received training on the questionnaire, and all were fluent in the local vernacular languages.
Data were analysed using Stata version 12.0. Descriptive statistics used employed means and standard deviations (SDs) or medians and interquartile ranges (IQRs) (for continuous variables) and proportions (for categorical variables). We compared knowledge scores on subgroups using Student's f-tests and Fisher's exact tests. All statistical tests were two-sided (alpha=0.05).
HIV-infected pregnant women
A total of 201 HIV-infected pregnant women were interviewed (Table 1). The mean age was 27.7 years (SD [+ or-] 4.8); median gestational age was 20 weeks (IQR 16-24) at the first antenatal visit and 32 weeks (IQR 24-32) at the time of the interview. The majority of women (71.5%) discovered that they were HIV-infected in the index pregnancy. Of the women diagnosed in a previous pregnancy, 84.1% (37/44) had previously taken single-dose NVP for PMTCT. A baseline [CD4.sup.+] cell count was available for 92.0% of the participants: median 395 cells/[micro]l (IQR 294-500); mean 420 cells/[micro]l (SD [+ or -] 190).
Overall, 87.5% (175/200) of the women had disclosed their HIV status; the majority (90.9%; 159/175) had done so to their partners. This finding did not differ according to timing of HIV diagnosis. Of the women who discovered that they were HIV-infected in the index pregnancy, 68.0% had disclosed their status. There were various reasons for non-disclosure to the partner, including fear that the partner would leave, be violent, or accuse the woman of being unfaithful and infecting him with HIV. Less than half (45.3%) of the women knew their partner's HIV status. There was a significant difference in the knowledge of the partner's HIV status between women who had, and those who had not disclosed their HIV status: 89 (50.9%) v. 0 (0%) knew the partner's HIV status, respectively (p<0.001). Of the partners with known HIV status, 81.3% were HIV-infected.
Of the women, 62.7% and 43.3% had accurate knowledge on antenatal and intra-partum prophylaxis, respectively. Overall, 97.5% (196/201) had received some counselling, 67.7% had received more than one counselling session, 88.6% (178/201) felt that the time spent on counselling was adequate, and 33.5% were part of a support group. There was no significant difference in knowledge between pregnant women who were members of a support group (mean score 5.29; SD [+ or-] 0.98)), and those who were not (mean score 5.18; SD [+ or-] 1.41) (p=0.542) (Table 2). There was a significant difference in knowledge between women who were already receiving AZT prophylaxis (mean score 5.44; SD [+ or-] 1.18) and those who were not (mean score 4.94; SD [+ or-] 1.34) (Table 3) (p=0.005).
Of the healthcare workers interviewed, 43.8% were professional nurses and 37.5% were lay counsellors; the majority (81.3%) had been in their current position for longer than a year (Table 4). Less than a half (47.5%) were satisfied with their working conditions. The most dissatisfaction was in terms of remuneration; only 28.8% were satisfied with their salary. In terms of workload, 80.0% of the workers felt that the new PMTCT programme increased their workload, and 92.5% felt that there was a need for more staff for the programme.
Most healthcare workers were satisfied with their knowledge of the PMTCT guidelines (80.0%) and with their general knowledge of HIV/AIDS (91.3%). In managing HIV-infected pregnant women, 96.3% were satisfied with their competence. Training received on the new guidelines was perceived to be adequate by 63.6%. The mean score for the workers' knowledge of the PMTCT guidelines was 5.15 (SD [+ or-] 1.85): 5.41 (SD [+ or-] 1.56) for professional nurses v. 5.19 (SD [+ or-] 1.89) for lay counsellors (p=0.586). There was no significant difference between the mean score of those who were satisfied with their knowledge of the guidelines (5.29; SD [+ or-] 1.88) and those who were not (4.56; SD [+ or-] 1.63) (p=0.157) (Table 5). There was also no difference between the mean score of healthcare workers who thought that the training they received was adequate (5.10; SD [+ or-] 1.9) and those who did not (5.14; SD [+ or-] 1.7) (p=0.926).
A high percentage of healthcare workers (86.3%) thought that HIV-infected pregnant women did not disclose their HIV status. There were a number of adverse opinions about HIV-infected women having children: 21.3% of healthcare workers thought that HIV-infected individuals should not have children; 53.8% thought HIV-infected individuals were having too many children; and 46.3% thought that social grants were an incentive for HIV-infected women to have children.
In this cross-sectional survey, several challenges were identified in the Soweto PMTCT programmes. The majority of pregnant women discovered that they were HIV-infected during pregnancy, and although disclosure to partners was high, less than half knew their partner's HIV status. There were important deficiencies in the women's knowledge of the available PMTCT interventions, despite receiving counselling and their perception that the counselling that they received was adequate. Neither the number of counselling sessions received, nor participation in a support group, had an impact on the quality of knowledge.
Staff in the PMTCT programme felt well prepared and well informed prior to the rollout of the updated PMTCT programme. The majority thought that the training received was adequate and almost all felt confident about managing HIV-infected women; yet, there were several important gaps in the knowledge of the PMTCT guidelines. Job satisfaction was low, mostly in terms remuneration. Moreover, several staff members expressed negative opinions about HIV-infected women having children.
The findings of this cross-sectional survey have important implications for PMTCT programmes in SA. Routine HIV testing for women, and men, of reproductive age needs to be encouraged, and linkages to care provided for those who test HIV-positive. This is especially important in women who are ART-eligible, as they carry a high risk of mother-to-child transmission, and ART initiated preconception decreases this risk significantly.  It will be important to assess the impact of the SA national HIV counselling and testing (HCT) drive on testing outside of pregnancy. 
Unpublished data from the Soweto PMTCT programmes indicate that the number of pregnant women presenting for antenatal care with a known HIV-positive status and already receiving ART has increased in the past 2 years (C Mnyani, unpublished data). The rate of disclosure among HIV-infected pregnant women in this survey was higher than that reported for most of sub-Saharan Africa, but similar to the findings of another study conducted in SA. [16-18] Disclosure has been shown to be important in women's uptake and adherence to PMTCT interventions. 
Our data on the women's knowledge of PMTCT interventions suggest that the quality of counselling given can be improved. Incorrect information, and hence incorrect practices, will be harmful in the context of PMTCT and may significantly increase the risk of mother-to-child transmission. While health knowledge is only one component of quality of care, there is evidence to suggest that poor quality of counselling, which translates to poor patient knowledge, is an important contributing factor to non-adherence to PMTCT interventions. [5,19] Poor quality of counselling has been reported even in well-functioning PMTCT sites where counsellors, some nurses, had received structured training.  The SA public healthcare sector depends on the services of lay counsellors who receive a stipend, and also receive variable training. Counselling services are often interrupted, and there is evidence to suggest that this has a negative effect on PMTCT services. 
As we scale up PMTCT programmes and introduce more complex interventions, staff preparedness, including knowledge, needs to be improved. [22,23] There needs to be a review and standardisation of training providers, and also of training content. Support using trained peers who are experts in HIV care and management has been shown to be an important intervention in building capacity.  Negative staff attitudes towards HIV-infected women also need to be addressed. There is evidence that HIV-infected women who fear and/or experience stigmatisation may avoid participating in PMTCT programmes. 
While our findings do have important implications, there are several limitations to this survey. Like all questionnaire-based research, the results may have been influenced by reporting biases. In this case, participants may have felt social desirability to report satisfaction with their PMTCT-related knowledge, but this potential bias was unlikely to have influenced their ability to report factual knowledge correctly. In addition, although the study was conduced under a different set of PMTCT policy guidelines, the findings are particularly noteworthy given the subsequent implementation of more complex PMTCT guidelines in SA and many other parts of Africa. The study was conducted in one urban community of high HIV prevalence and with established PMTCT services, and the results should be generalised to other settings with caution. Healthcare workers were generally reluctant to be interviewed, and this warrants further investigation. Also, we used a consecutive sampling strategy; although routine in this form of health services research, this may be more prone to bias than random sampling strategies. There are plans to perform a similar survey to assess experiences with, and knowledge of the latest SA PMTCT guidelines. Despite the limitations, there are strengths to the survey that warrant merit, including the large number of pregnant women and different categories of staff who were interviewed.
There are still several challenges in PMTCT services. Most importantly, knowledge of PMTCT interventions is surprisingly low in both clients and healthcare providers, and there is a need for enhanced interventions to improve the quality of care in PMTCT services. This is particularly important as PMTCT interventions become more complex during the ante-and postnatal periods.
Acknowledgements. The Anova Health Institutes Soweto PMTCT programme is supported by the US President's Emergency Plan for AIDS Relief (PEPFAR) via the US Agency for International Development (USAID) (cooperative agreement no. 674-A-00-08-00009-00). The views expressed here do not necessarily reflect those of PEPFAR or USAID. We acknowledge the patients and staff at all the antenatal clinics sampled in Soweto.
Conflict of interest. The authors declare no conflicts of interest. No external funding was used for this study.
[1.] UNICEF 2010. South Africa: PMTCT. New York: UNICEF, 2010. http://www.unicef.org/aids/files/ SAfrica_PMTCTFactsheet_2010.pdf (accessed 18 November 2011).
[2.] UNAIDS 2011. World AIDS Day Report 2011. Geneva: Joint United Nations Programme on HIV/ AIDS (UNAIDS) and World Health Organization (WHO). http://www.unaids.org/en (accessed 18 November 2011).
[3.] Sprague C, Chersich MF, Black V. Health system weaknesses constrain access to PMTCT and maternal HIV services in South Africa: A qualitative enquiry. AIDS Res Ther 2011;8:10. [http://dx.doi. org/10.1186/1742-6405-8-10]
[4.] Delva W, Draper B, Temmerman M. Implementation of single-dose nevirapine for prevention of MTCT of HIV--lessons from Cape Town. S Afr Med J 2006;96(8):706-709.
[5.] Nkonki LL, Doherty TM, Hill Z, et al. Missed opportunities for participation in prevention of mother-to-child transmission programmes: Simplicity of nevirapine does not necessary lead to optimal uptake, a qualitative study. AIDS Res Ther 2007;4:27. [http://dx.doi.org/10.1186/1742-6405-4-27]
[6.] Dohrn J, Nzama B, Murrnam M. The impact of HIV scale-up on the role of nurses in South Africa: Time for a new approach. J Acquir Immune Defic Syndr 2009;52:S27-S29. [http://dx.doi.org/10.1097/ QAI.0b013e3181bbc9e4]
[7.] Salyer JLH, Walusimbi ML, Fitzpatrick JJ. Knowledge and Attitudes of Ugandan Midwives Regarding HIV. Journal of the Association of Nurses in AIDS Care 2008;19(2):105-113. [http:// dx.doi.org/10.1016/j.jana.2008.01.001]
[8.] McIntyre J, Lallemant M. The prevention of mother-to-child transmission of HIV: are we translating scientific success into programmatic failure? Curr Opin HIV AIDS 2008;3:139-145. [http://dx.doi. org/10.1097/COH.0b013e3282f5242a]
[9.] Stringer EM, Ekouevi DK, Coetzee D, et al. Coverage of nevirapine-based services to prevent mother-to-child HIV transmission in 4 African countries. JAMA 2010;304(3):293-302. [http:// dx.doi.org/10.1001/jama.2010.990]
[10.] Barry OM, Bergh AM, Makin JD, et al. Development of a measure of the patient-provider relationship in antenatal care and its importance in PMTCT. AIDS Care 2012;24(6):680-686. [http://dx.doi.org/10.108 0/09540121.2011.630369]
[11.] Doherty TM, McCoy D, Donohue S. Health system constraints to optimal coverage of the prevention of mother-to-child HIV transmission programme in South Africa: Lessons from the implementation of the national pilot programme. Afr Health Sci 2005;5(3):213-218.
[12.] Doherty T, Chopra M, Nsibande D, et al. Improving the coverage of the PMTCT programme through a participatory quality improvement intervention in South Africa. BMC Public Health 2009;5(9):406. [http://dx.doi.org/10.1186/1471-2458-9-406]
[13.] South African National Department of Health. National Department of Health: Policy and Guidelines for the Implementation of the PMTCT Programme. Pretoria: DoH, 2008. http://www.info. gov.za (accessed 28 November 2011).
[14.] Townsend CL, Cortina-Borja M, Peckham CS, et al. Low rates of mother-to-child transmission of HIV following effective pregnancy interventions in the United Kingdom and Ireland, 2000-2006. AIDS 2008;22(8):973-981. [http://dx.doi.org/10.1097/ QAD.0b013e3282f9b67a]
[15.] Motsoaledi A. Outline of the national HIV Counselling and Testing (HCT) campaign, 2011. http://www.info.gov.za/ speeches/2010/10032611051001.htm (accessed 28 November 2011).
[16.] Medley A, Garcia-Moreno C, McGill S, et al. Rates, barriers and outcomes of HIV serostatus disclosure among women in developing countries: Implications for prevention of mother-to-child transmission programmes. Bull World Health Organ 2004;82(4):299-307.
[17.] Visser MJ, Neufeld S, de Villiers A, et al. To tell or not to tell: South African women's disclosure of HIV status during pregnancy. AIDS Care 2008;20(9):1130-1145. [http://dx.doi. org/10.1080/09540120701842779]
[18.] Makin JD, Forsyth BW, Visser MJ, et al. Factors affecting disclosure in South African HIV-positive pregnant women. AIDS Patient Care STDs 2010;22(11):907-916. [http://dx.doi.org/10.1089/ apc.2007.0194]
[19.] Baek C, Rutenberg N. Implementing programs for the prevention of mother-to-child HIV transmission in resource-constrained settings: Horizons studies, 1999-2007. Public Health Rep 2010;125(2):293-304.
[20.] Chopra M, Doherty T, Jackson D, et al. Preventing HIV transmission to children: Quality of counselling of mothers in South Africa. Acta Paediatr 2005;94:357-363. [http://dx.doi. org/10.1111/j.1651-2227.2005.tb03080.x]
[21.] Black V, Sprague C, Chersich MF. Interruptions in payments for lay counsellors affects HIV testing at antenatal clinics in Johannesburg. S Afr Med J 2011;101:407-408.
[22.] Simba D, Kamwela J, Mpembeni R, et al. The impact of scaling-up prevention of mother-to-child transmission (PMTCT) of HIV infection on the human resource requirement: the need to go beyond numbers. Int J Health Plann Mgmt 2010;25:17-29. [http://dx.doi.org/10.1002/hpm.950]
[23.] Youngleson MS, Nkurunziza P, Jennings K, et al. Improving a mother-to-child HIV transmission programme through health system redesign: Quality improvement, protocol adjustment and resource addition. PLOS One 2010;5(11):e13891. [http:// dx.doi.org/10.1371/journal.pone.0013891.s001]
[24.] Rahangdale L, Banandur P, Sreenivas A, et al. Stigma as experienced by women accessing prevention of parent-to-child transmission of HIV services in Karnataka, India. AIDS Care 2010;22(7):836-842. [http://dx.doi.org/10.1080/09540120903499212]
C N Mnyani, (1) BA, MB ChB, FCOG (SA); J A McIntyre, (1,2) MB ChB, FRCOG
(1) Anova Health Institute, Johannesburg, South Africa
(2) Centre for Infectious Diseases Epidemiology and Research, School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa
Corresponding author: C N Mnyani (firstname.lastname@example.org)
Table 1. Characteristics of pregnant women (N=201) Characteristics Age (years), mean ([+ or -] SD) 27.7 ([+ or -] 4.8) Parity, median (IQR) 2 (1-2) Gravidity, median (IQR) 2 (1-3) Gestational age at booking (weeks), 20 (16-24) median (IQR) Gestational age at interview (weeks), 32 (24-32) median (IQR) [CD4.sup.+] cell count 395 (294-500) (cells/[micro]l), median (IQR) When HIV status discovered (N=200) Current pregnancy 143 (71.5) Previous pregnancy 44 (22.0) Outside of pregnancy 13 (6.5) Disclosed HIV status (N=199), n (%) 175 (87.9) To whom disclosed, n (%) Partner 159 (90.9) Parent 61 (34.9) Sibling 42 (24.0) Friend 30 (17.1) Other 5 (2.9) SD = standard deviation; IQR = interquartile range. Table 2. Characteristics and knowledge of pregnant women who were members of a support group (N=67) v. those who were not (N=133) Yes Members of a support group n (%) Characteristics Age (years) <25 18 (26.9) 25-35 47 (70.1) >35 2 (3.0) Parity [less than or equal to] 2 58 (86.6) 5-Mar 9 (13.4) When HIV status discovered: Current pregnancy 44 (65.7) Previous pregnancy 21 (31.3) Outside of pregnancy 2 (3.0) Disclosed HIV status 56 (83.6) Correct knowledge AZT prophylaxis Indication 66 (98.5) Timing of initiation 64 (95.5) Duration of use 26 (38.8) Prophylaxis during labour 18 (26.9) Need for infant prophylaxis 63 (94.0) Type of infant prophylaxis 7 (10.5) Duration of infant prophylaxis 52 (77.6) Duration of exclusive breastfeeding 59 (88.1) Overall score, mean ([+ or -] SD) 5.3 ([+ or -] 0.98) No Members of a support group n (%) p-value Characteristics Age (years) <25 35 (26.3) 25-35 91 (68.4) >35 7 (5.3) 0.764 Parity [less than or equal to] 2 109 (81.9) 5-Mar 24 (18.1) 0.407 When HIV status discovered: Current pregnancy 98 (74.2) Previous pregnancy 23 (17.4) Outside of pregnancy 11 (8.3) 0.043 Disclosed HIV status 118 (88.7) 0.356 Correct knowledge AZT prophylaxis Indication 124 (93.2) 0.143 Timing of initiation 119 (90.2) 0.188 Duration of use 99 (74.4) <0.001 Prophylaxis during labour 69 (51.9) 0.001 Need for infant prophylaxis 111 (83.5) 0.036 Type of infant prophylaxis 18 (13.5) 0.553 Duration of infant prophylaxis 62 (39.1) <0.001 Duration of exclusive breastfeeding 87 (65.4) 0.001 Overall score, mean ([+ or -] SD) 5.2 ([+ or -] 1.41) 0.542 AZT = zidovudine; SD = standard deviation. Table 3. Difference in knowledge in pregnant women who were already on zidovudine (AZT) prophylaxis (N=114) and those who were not (N=86) Yes AZT prophylaxis n (%) Correct knowledge Indication for AZT 111 (97.4) Timing of AZT initiation 101 (88.6) Duration of use of AZT 79 (69.3) Intrapartum prophylaxis 63 (55.3) Score, mean ([+ or -] SD) 5.44 ([+ or -] 1.18) No AZT prophylaxis n (%) p-value Correct knowledge Indication for AZT 79 (91.9) 0.137 Timing of AZT initiation 82 (95.4) 0.125 Duration of use of AZT 47 (54.7) 0.034 Intrapartum prophylaxis 24 (27.9) <0.001 Score, mean ([+ or -] SD) 4.94 ([+ or -] 1.34) 0.005 Table 4. Characteristics of healthcare workers (N=80) Characteristics n (%) Gender (N=79) Female 74 (93.7) Staff categories Professional nurse 35 (43.8) Auxiliary nurse 9 (11.3) Lay counsellor 30 (37.5) Other 6 (7.5) Time in current position <6 months 7 (8.8) 6 months-1 year 8 (10.0) >1-5 years 33 (41.3) >5-10 years 22 (27.5) >10 years 10 (12.5) Table 5. Characteristics and knowledge of healthcare workers who were satisfied with their knowledge of PMTCT (N=64) v. those who were not (N=16) Satisfied with knowledge of PMTCT Yes, n (%) Characteristics Staff categories Midwife 14 (21.9) PMTCT coordinator 10 (15.6) PCR nurse 4 (6.1) Lay counsellor 28 (43.8) Other 8 (12.5) Time in current position <6 months 4 (6.3) 6 months-1 year 7 (10.9) 2-5 years 30 (46.9) 6-10 years 19 (29.7) >10 years 4 (6.3) Correct knowledge Single-dose NVP Efficacy 55 (85.9) Repeat in same pregnancy 52 (81.3) Use in subsequent pregnancies 51 (79.7) ART use in pregnancy 44 (68.8) Sero-conversion during pregnancy 42 (65.5) Exclusive breastfeeding 26 (40.6) and risk of MTCT Extended breastfeeding 50 (78.1) and risk of MTCT Contraception for 19 (29.7) HIV-infected women Overall score, mean ([+ or -]SD) 5.3 ([+ or -]1.88) Satisfied with knowledge of PMTCT No n (%) p-value Characteristics Staff categories Midwife 6 (37.5) PMTCT coordinator 0 (0) PCR nurse 2 (12.5) Lay counsellor 2 (12.5) Other 6 (37.5) Time in current position <6 months 3 (18.8) 6 months-1 year 1 (6.3) 2-5 years 3 (18.8) 6-10 years 3 (18.8) >10 years 6 (37.5) Correct knowledge Single-dose NVP Efficacy 11 (68.8) 0.211 Repeat in same pregnancy 10 (62.5) 0.410 Use in subsequent pregnancies 12 (75.0) 0.933 ART use in pregnancy 8 (50.0) 0.191 Sero-conversion during pregnancy 10 (62.5) 0.754 Exclusive breastfeeding 9 (56.3) 0.190 and risk of MTCT Extended breastfeeding 12 (75.0) 0.704 and risk of MTCT Contraception for 1 (6.3) 0.105 HIV-infected women Overall score, mean ([+ or -]SD) 4.6 ([+ or -] 1.63) 0.157 PMTCT = prevention of mother-to-child transmission of HIV; PCR nurse = nurse responsible for HIV PCR tests in infants; NVP = nevirapine; ART = antiretroviral therapy; MTCT = mother-to-child transmission of HIV.
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||ORIGINAL ARTICLE|
|Author:||Mnyani, C.N.; McIntyre, J.A.|
|Publication:||Southern African Journal of HIV Medicine|
|Date:||Jun 1, 2013|
|Previous Article:||A suicide risk screening scale for HIV-infected persons in the immediate post-diagnosis period.|
|Next Article:||Parental presence within households and the impact of antiretroviral therapy in Khayelitsha, Cape Town.|